Skip to content

Biodesix, Inc. BDSX Operating lease liabilities

Operating lease liabilities at other companies

NeoGenomics logo
NeoGenomicsNEO
Veracyte logo
VeracyteVCYT
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s operating lease liabilities?
Biodesix, Inc. (BDSX) reported operating lease liabilities of -$341K in Q1 2026.
How has Biodesix, Inc.'s operating lease liabilities changed year-over-year?
Biodesix, Inc.'s operating lease liabilities decreased by 1794.4% year-over-year, from -$18K to -$341K.
What is the long-term trend for Biodesix, Inc.'s operating lease liabilities?
Over 2 years (2022 to 2025), Biodesix, Inc.'s operating lease liabilities has grown at a -8.2% compound annual growth rate (CAGR), from -$937K to -$789K.